Baidu
map

NEJM:乳腺癌筛查指南更新——IARC观点

2015-06-09 姜缓缓 编译 中国医学论坛报今日肿瘤微信公众号

乳腺癌筛查的目的是通过对无症状女性进行早期检测,降低这种癌症的死亡率,以及与疾病晚期相关的发病率。使筛查的作用达到最大化的关键是早期获取有效的诊断和治疗。而筛查的综合质量是保持筛查利弊平衡的重中之重。  6月3日《新英格兰医学杂志》(New Engl J Med)在线发布国际癌症研究机构(IARC)乳腺癌筛查指南。IARC此次对其2002发布的乳腺癌筛查手册的更新主要基于以下几个方面原因。1.晚期

乳腺癌筛查的目的是通过对无症状女性进行早期检测,降低这种癌症的死亡率,以及与疾病晚期相关的发病率。使筛查的作用达到最大化的关键是早期获取有效的诊断和治疗。而筛查的综合质量是保持筛查利弊平衡的重中之重。
  
6月3日《新英格兰医学杂志》(New Engl J Med)在线发布国际癌症研究机构(IARC)乳腺癌筛查指南。IARC此次对其2002发布的乳腺癌筛查手册的更新主要基于以下几个方面原因。1.晚期乳腺癌治疗的进步和关于针对过度诊断要求复议。2.鉴于最新的研究进展,应该对乳腺X线筛查计划最佳实施的定义(例如,哪个年龄组应进行筛查和筛查频率)进行修订。3.针对临床乳房检查和自检的一些研究结果,需要对这些筛查方法进行评估;现在需要对2002年后新出现的、钼靶X线之外的影像学技术(之前未被评价)进行严谨的科学评价。4.要对乳腺癌高危妇女的筛查进行彻底的重新评估,尤其是是对那些可能作为替代方法的数据更新进行评估。




Table 1.Evaluation of Evidence Regarding the Beneficial and Adverse Effects of Different Methods of Screening for Breast Cancer in the General Population and in High-Risk Women.

原始出处:

Béatrice Lauby-Secretan, Ph.D., Chiara Scoccianti, Ph.D., Dana Loomis, Ph.D., Lamia Benbrahim-Tallaa, Ph.D., Véronique Bouvard, Ph.D., Franca Bianchini, Ph.D., and Kurt Straif, M.P.H., M.D., Ph.D. for the International Agency for Research on Cancer Handbook Working Group.Breast-Cancer Screening — Viewpoint of the IARC Working Group.New Engl J Med, June 3, 2015.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=971819, encodeId=7f379e181967, content=希望有更多更好指南 , beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c8e5452710, createdName=ms4000001114161496, createdTime=Tue Jun 08 13:03:15 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071441, encodeId=585a20e144108, content=<a href='/topic/show?id=78a192865a' target=_blank style='color:#2F92EE;'>#IARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9286, encryptionId=78a192865a, topicName=IARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Feb 20 17:18:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988216, encodeId=061a198821651, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Wed Feb 17 09:18:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30724, encodeId=347930e2424, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Jul 04 23:49:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455947, encodeId=1d07145594e7c, content=<a href='/topic/show?id=d1fc23e69b7' target=_blank style='color:#2F92EE;'>#乳腺癌筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23769, encryptionId=d1fc23e69b7, topicName=乳腺癌筛查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 11 07:18:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26638, encodeId=c8a526638f6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:01:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
    2021-06-08 ms4000001114161496

    希望有更多更好指南

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=971819, encodeId=7f379e181967, content=希望有更多更好指南 , beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c8e5452710, createdName=ms4000001114161496, createdTime=Tue Jun 08 13:03:15 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071441, encodeId=585a20e144108, content=<a href='/topic/show?id=78a192865a' target=_blank style='color:#2F92EE;'>#IARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9286, encryptionId=78a192865a, topicName=IARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Feb 20 17:18:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988216, encodeId=061a198821651, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Wed Feb 17 09:18:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30724, encodeId=347930e2424, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Jul 04 23:49:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455947, encodeId=1d07145594e7c, content=<a href='/topic/show?id=d1fc23e69b7' target=_blank style='color:#2F92EE;'>#乳腺癌筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23769, encryptionId=d1fc23e69b7, topicName=乳腺癌筛查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 11 07:18:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26638, encodeId=c8a526638f6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:01:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
    2016-02-20 jambiya
  3. [GetPortalCommentsPageByObjectIdResponse(id=971819, encodeId=7f379e181967, content=希望有更多更好指南 , beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c8e5452710, createdName=ms4000001114161496, createdTime=Tue Jun 08 13:03:15 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071441, encodeId=585a20e144108, content=<a href='/topic/show?id=78a192865a' target=_blank style='color:#2F92EE;'>#IARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9286, encryptionId=78a192865a, topicName=IARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Feb 20 17:18:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988216, encodeId=061a198821651, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Wed Feb 17 09:18:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30724, encodeId=347930e2424, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Jul 04 23:49:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455947, encodeId=1d07145594e7c, content=<a href='/topic/show?id=d1fc23e69b7' target=_blank style='color:#2F92EE;'>#乳腺癌筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23769, encryptionId=d1fc23e69b7, topicName=乳腺癌筛查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 11 07:18:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26638, encodeId=c8a526638f6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:01:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=971819, encodeId=7f379e181967, content=希望有更多更好指南 , beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c8e5452710, createdName=ms4000001114161496, createdTime=Tue Jun 08 13:03:15 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071441, encodeId=585a20e144108, content=<a href='/topic/show?id=78a192865a' target=_blank style='color:#2F92EE;'>#IARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9286, encryptionId=78a192865a, topicName=IARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Feb 20 17:18:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988216, encodeId=061a198821651, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Wed Feb 17 09:18:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30724, encodeId=347930e2424, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Jul 04 23:49:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455947, encodeId=1d07145594e7c, content=<a href='/topic/show?id=d1fc23e69b7' target=_blank style='color:#2F92EE;'>#乳腺癌筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23769, encryptionId=d1fc23e69b7, topicName=乳腺癌筛查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 11 07:18:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26638, encodeId=c8a526638f6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:01:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
    2015-07-04 Gsurgeon

    好文

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=971819, encodeId=7f379e181967, content=希望有更多更好指南 , beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c8e5452710, createdName=ms4000001114161496, createdTime=Tue Jun 08 13:03:15 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071441, encodeId=585a20e144108, content=<a href='/topic/show?id=78a192865a' target=_blank style='color:#2F92EE;'>#IARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9286, encryptionId=78a192865a, topicName=IARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Feb 20 17:18:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988216, encodeId=061a198821651, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Wed Feb 17 09:18:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30724, encodeId=347930e2424, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Jul 04 23:49:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455947, encodeId=1d07145594e7c, content=<a href='/topic/show?id=d1fc23e69b7' target=_blank style='color:#2F92EE;'>#乳腺癌筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23769, encryptionId=d1fc23e69b7, topicName=乳腺癌筛查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 11 07:18:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26638, encodeId=c8a526638f6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:01:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=971819, encodeId=7f379e181967, content=希望有更多更好指南 , beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c8e5452710, createdName=ms4000001114161496, createdTime=Tue Jun 08 13:03:15 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071441, encodeId=585a20e144108, content=<a href='/topic/show?id=78a192865a' target=_blank style='color:#2F92EE;'>#IARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9286, encryptionId=78a192865a, topicName=IARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Feb 20 17:18:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988216, encodeId=061a198821651, content=<a href='/topic/show?id=327e563967e' target=_blank style='color:#2F92EE;'>#指南更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56396, encryptionId=327e563967e, topicName=指南更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Wed Feb 17 09:18:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30724, encodeId=347930e2424, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Jul 04 23:49:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455947, encodeId=1d07145594e7c, content=<a href='/topic/show?id=d1fc23e69b7' target=_blank style='color:#2F92EE;'>#乳腺癌筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23769, encryptionId=d1fc23e69b7, topicName=乳腺癌筛查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 11 07:18:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26638, encodeId=c8a526638f6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:01:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
    2015-06-09 huaxipanxing

    看看

    0

相关资讯

Lancet:狄诺塞麦可以减少乳腺癌使用芳香酶抑制剂骨折的风险

    背景  辅助内分泌治疗危及乳腺癌患者的骨骼健康,造成骨质疏松,骨质疏松和骨折。抗吸收治疗,例如二膦酸盐可预防和抵消这些副作用。在这项试验中,研究人员试图调查抗RANK配体抗体狄诺塞麦绝在绝经后的效果,芳香酶抑制剂治疗早期激素受体阳性乳腺癌患者的效果。    方法  在这项前瞻性的,双盲,安慰剂对照,3期试验中,绝经后早期激素受体阳

Nature:科学家破解乳腺癌“骨转移”途径,全新疗法诞生

5月27日,在线发表于《自然》杂志上的一项研究中,科学家们发现乳腺癌细胞能分泌蛋白lysyl oxidase(LOX) ,经血液循环到达骨骼,产生溶骨作用,从而帮助乳腺癌细胞在骨骼种植生长(转移)。约85%的乳腺癌会扩散至全身,最终到达骨骼,使癌症更难治疗。这项惊人的发现打开了一个全新的研究途径,研究人员认为通过保护骨骼不受癌细胞这种“狡诈”的影响,可以阻止癌细胞的扩散。科学家们发现,继发性癌症的

NEJM: 乳腺癌手术患者特别注意事项

根据耶鲁癌症中心的研究发现,在部分乳房切除术时,移除更多一些的组织可以为成千上万的乳腺癌患者省去第二次手术。这项发现于5月30日在线发表在New England Journal of Medicine杂志上,且在2015年芝加哥举行的美国临床癌症协会年会上有所报道。 在美国,每年近30万女性被诊断为乳腺癌,超过一半的患者接受部分乳房切除术来移除病灶,同时保留部分乳腺。然而,大约20%到40%

ASCO 2015:两项乳腺癌靶向治疗研究---CALGB 40503和NeoSpher研究

河南省肿瘤医院 河南省乳腺病诊疗中心 闫敏 发自 美国芝加哥研究1:评价贝伐珠单抗加来曲唑一线治疗激素受体阳性转移性乳腺癌的Ⅲ期临床研究(CALGB 40503)报告者:美国纽约纪念斯隆-凯特林癌症中心Maura N. Dickler摘要号:501背景:临床前研究表明,雌激素可在生理和病理条件下调节血管生成,乳腺肿瘤中血管内皮生长因子(VEGF)的高表达与降低内分泌治疗反应性相关,研究者开展了一项

另类乳腺癌宣传:「胸夹可乐」大挑战?

与去年夏天兴起的冰桶挑战相比,今年的“胸夹可乐”挑战[hold a coke with your boobs challenge]让人很难去在乎这种做法的目的是什么,说是为了让人们关注乳腺癌,其实没有什么其他目的,就是为了找个借口秀胸部罢了。 和之前的把铅笔放在袜子里来宣传睾丸癌的做法,以及其他许多你可能记得在社交网络上出现过的其他一些引人注意的“宣传”一样,这次的胸夹可乐挑战让人们能够展示他们

ASCO 2015:年度“颁奖盛典”

1月20日,美国临床肿瘤学会(ASCO)在《临床肿瘤学杂志》(JClin Oncol)上在线发布了《ASCO年度报告:2015临床肿瘤学进展》,不仅保持了以往传统,对上一年的癌症预防、治疗和患者照护有重大影响的临床进展进行探讨,而且还首次发布ASCO年度进展(AdvanceoftheYear)。 年度进展 ASCO年度报告首次发布年度进展(Advanceof the

Baidu
map
Baidu
map
Baidu
map